Results 91 to 100 of about 13,549 (163)

Proteasome inhibition as a potential therapeutic target in thymic cancer

Cell Death and Disease
Multimodal radio-chemotherapy is the mainstay of treatment for unresectable thymoma (TH) and thymic carcinoma (TC), but there is an urgent need for other therapeutic strategies in these rare tumors.
Satoru Okada, Louisa Benter, Leon Schrell, Denise Müller, Selen Selcen, Hanibal Bohnenberger, Carolin Schneider, Günter Schneider, Melanie Lohrberg, Raphael Koch, Tobias R. Overbeck, Alexander von Hammerstein-Equord, Stefan Welter, Marc Hinterthaner, Lucia Cordes, Katayoon Shirneshan, Christoph Netzer, Masayoshi Inoue, Alexander Marx, Philipp Ströbel, Stefan Küffer   +20 more
doaj   +1 more source

Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma. [PDF]

Ann Hematol
Potthoff K, Uhlig J, Heyde EV, Losem C, Nusch A, Ammon A, Schöttker B, Schulz H, Janssen J, Welslau M, Wilop S, Vannier C, Hanselmann J, Serrer L, Woerner SM, Koszinowski S, Engelhardt M, Knauf W.   +17 more
europepmc   +1 more source

Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study. [PDF]

Ther Adv Hematol
Fan H, Feng X, Wei R, Zhang X, Li T, Liu L, Wang H, Sun L, Shi X, Zhao H, Li Z, Cui J, Xu J, Ma J, Feng X, Wang W.   +15 more
europepmc   +1 more source

Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200. [PDF]

Blood Adv
Bashir Q, Thall PF, Kawedia JD, Xu X, Knape CG, Delgado R, Nieto Y, Saini N, Aljawai YM, Srour SA, Ramdial JL, Hosing C, Popat UR, Oran B, Kebriaei P, Ahmed S, Pasvolsky O, Patel K, Thomas S, Gaballa M, Ye C, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH.   +24 more
europepmc   +1 more source

Targeting HDAC and proteostasis to eradicate quiescent cancer cells. [PDF]

Cancer Gene Ther
Jiang Q, Ertel M, Arrigo A, Hijazzi A, Sannino S, Goeckeler-Fried JL, Sagan A, Beddows I, Varghese BA, Brown DD, Stallaert W, Lee A, Clark AM, Shen H, Brodsky JL, Osmanbeyoglu HU, Buckanovich RJ.   +16 more
europepmc   +1 more source

Anticancer proteasome inhibitors are detrimental to the growth of Toxoplasma gondii in vitro. [PDF]

BMC Res Notes
Zhang M, Guiton PS.
europepmc   +1 more source

A Simulation-Based Assessment of Dosage Regimen Appropriateness for Multiple Myeloma Medicines Reflecting Demographic and Ethnic Differences. [PDF]

Clin Transl Sci
Kang M, Choi S, Park SS, Han S, Han S.
europepmc   +1 more source

Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma. [PDF]

Cells
Weigl EJ, Demir S, Hotes A, Indersie E, Branchereau S, Cairo S, Kappler R.   +6 more
europepmc   +1 more source

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma. [PDF]

Br J Haematol
Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Ahmed S, Deeba RE, Tang G, Aljawai Y, Lee HC, Patel KK, Gaballa MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O.   +22 more
europepmc   +1 more source

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone. [PDF]

Future Oncol
Yong K, Martin T, Dimopoulos MA, Mikhael J, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Moreau P.   +19 more
europepmc   +1 more source